一项评估 Durvalumab 与 Oleclumab 或 Durvalumab 与 Monalizumab 联合放化疗对 III 期不可切除非小细胞肺癌患者影响的全球研究 (PACIFIC-9)
Durvalumab 加 Oleclumab 和 Durvalumab 加 Monalizumab 治疗未进展的局部晚期(III 期)不可切除非小细胞肺癌 (NSCLC) 患者的 III 期、双盲、安慰剂对照、随机、多中心国际研究在最终的、基于铂的同步化放疗之后
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Anyang、中国、455000
- Research Site
-
Beijing、中国、100021
- Research Site
-
Changchun、中国、130021
- Research Site
-
Changsha、中国、410013
- Research Site
-
Changsha、中国、410008
- Research Site
-
Guangzhou、中国、510060
- Research Site
-
Guangzhou、中国、510062
- Research Site
-
Guangzhou、中国、510700
- Research Site
-
Hangzhou、中国、310022
- Research Site
-
Hangzhou、中国、310002
- Research Site
-
Hefei、中国、230031
- Research Site
-
Hefei、中国、133500
- Research Site
-
Kunming、中国、650118
- Research Site
-
Linhai、中国、317000
- Research Site
-
Nanchang、中国、330006
- Research Site
-
Nanning、中国、530021
- Research Site
-
Nantong、中国、226361
- Research Site
-
Neijiang、中国、641000
- Research Site
-
Ningbo、中国、315100
- Research Site
-
Shaoguan、中国、512027
- Research Site
-
Tianjin、中国、300060
- Research Site
-
Wuhan、中国、430079
- Research Site
-
Wuhan、中国、430022
- Research Site
-
Wuhan、中国、430071
- Research Site
-
Zhanjiang、中国、524001
- Research Site
-
Zhengzhou、中国、450008
- Research Site
-
Zhengzhou、中国、450000
- Research Site
-
Zhongshan、中国、528403
- Research Site
-
-
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6G 1Z2
- Research Site
-
-
Ontario
-
Barrie、Ontario、加拿大、L4M 6M2
- Research Site
-
Hamilton、Ontario、加拿大、L8V 5C2
- Research Site
-
Kingston、Ontario、加拿大、K7L 2V7
- Research Site
-
London、Ontario、加拿大、N6A 5W9
- Research Site
-
Mississauga、Ontario、加拿大、L5M 2N1
- Research Site
-
Toronto、Ontario、加拿大、M5G 2M9
- Research Site
-
-
Quebec
-
Rimouski、Quebec、加拿大、G5L 5T1
- Research Site
-
-
-
-
-
Hsinchu、台湾、300
- Research Site
-
New Taipei City、台湾、23561
- Research Site
-
Taichung、台湾、40705
- Research Site
-
Taichung、台湾、402
- Research Site
-
Taipei、台湾
- Research Site
-
Taipei、台湾、11490
- Research Site
-
Taoyuan City、台湾、333
- Research Site
-
-
-
-
-
Barranquilla、哥伦比亚、080020
- Research Site
-
Bogota D.C.、哥伦比亚、110131
- Research Site
-
Medellín、哥伦比亚、050034
- Research Site
-
Valledupar、哥伦比亚、200001
- Research Site
-
-
-
-
-
Ankara、土耳其(türkiye)、06230
- Research Site
-
Ankara、土耳其(türkiye)、06800
- Research Site
-
Ankara、土耳其(türkiye)、06010
- Research Site
-
Cordaleo、土耳其(türkiye)、35575
- Research Site
-
Diyarbakır、土耳其(türkiye)、21280
- Research Site
-
Goztepe Istanbul、土耳其(türkiye)
- Research Site
-
-
-
-
-
Barretos、巴西、14784-400
- Research Site
-
Belo Horizonte、巴西、30380-090
- Research Site
-
Florianópolis、巴西、88034-000
- Research Site
-
Fortaleza、巴西、60336-232
- Research Site
-
Jaú、巴西、17210-120
- Research Site
-
Natal、巴西、59075-740
- Research Site
-
Porto Alegre、巴西、91350-200
- Research Site
-
Porto Alegre、巴西、90610-001
- Research Site
-
Recife、巴西、52010-075
- Research Site
-
São Paulo、巴西、01323-903
- Research Site
-
Uberlândia、巴西、38408-150
- Research Site
-
Vitória、巴西、29043-260
- Research Site
-
-
-
-
-
Erfurt、德国、99089
- Research Site
-
Erlangen、德国、91054
- Research Site
-
Essen、德国、45147
- Research Site
-
Esslingen am Neckar、德国、73730
- Research Site
-
Georgsmarienhütte、德国、49124
- Research Site
-
Gütersloh、德国、33332
- Research Site
-
Hanover、德国、30459
- Research Site
-
Oldenburg、德国、26121
- Research Site
-
Würzburg、德国、97080
- Research Site
-
-
-
-
-
Brescia、意大利、25123
- Research Site
-
Florence、意大利、50134
- Research Site
-
Lucca、意大利、55100
- Research Site
-
Meldola、意大利、47014
- Research Site
-
Orbassano、意大利、10043
- Research Site
-
Parma、意大利、43126
- Research Site
-
Pavia、意大利、27100
- Research Site
-
Roma、意大利、00128
- Research Site
-
-
-
-
-
Himeji-shi、日本、670-8520
- Research Site
-
Hiroshima、日本、730-0011
- Research Site
-
Kashiwa、日本、227-8577
- Research Site
-
Kurume-shi、日本、830-0011
- Research Site
-
Natori-shi、日本、981-1293
- Research Site
-
Niigata、日本、951-8566
- Research Site
-
Osaka、日本、541-8567
- Research Site
-
Sendai、日本、980-0873
- Research Site
-
Tokushima、日本、770-8503
- Research Site
-
Toon-shi、日本、791-0295
- Research Site
-
Wakayama、日本、641-8510
- Research Site
-
-
-
-
-
Avignon、法国、84918
- Research Site
-
Besançon、法国、25030
- Research Site
-
Bordeaux、法国、33075
- Research Site
-
Clermont-Ferrand、法国、63000
- Research Site
-
Créteil、法国、94010
- Research Site
-
Lorient、法国、56322
- Research Site
-
Marseille、法国、13015
- Research Site
-
Montpellier、法国、34298
- Research Site
-
Rennes、法国、35033
- Research Site
-
Rouen、法国、76031
- Research Site
-
Toulouse、法国、31059
- Research Site
-
Villejuif、法国、94805
- Research Site
-
-
-
-
-
Bydgoszcz、波兰、85-796
- Research Site
-
Gdansk、波兰、80-952
- Research Site
-
Koszalin、波兰、75-581
- Research Site
-
Poznan、波兰、60-569
- Research Site
-
Siedlce、波兰、08-110
- Research Site
-
Tomaszów Mazowiecki、波兰、97-200
- Research Site
-
Warsaw、波兰、02-781
- Research Site
-
-
-
-
-
Bangkok、泰国、10300
- Research Site
-
Bangkok、泰国、10700
- Research Site
-
Hat Yai、泰国、90110
- Research Site
-
Khon Kaen、泰国、40002
- Research Site
-
Khon Kaen、泰国、40000
- Research Site
-
Lampang、泰国、52000
- Research Site
-
Muang、泰国、50200
- Research Site
-
Muang、泰国、22000
- Research Site
-
Mueang、泰国、20000
- Research Site
-
Naimuang、泰国、30000
- Research Site
-
-
-
-
-
Box Hill、澳大利亚、3128
- Research Site
-
East Melbourne、澳大利亚、3002
- Research Site
-
Elizabeth Vale、澳大利亚、5112
- Research Site
-
Gosford、澳大利亚、2250
- Research Site
-
Heidelberg、澳大利亚、3084
- Research Site
-
Kogarah、澳大利亚、2217
- Research Site
-
South Brisbane、澳大利亚、4101
- Research Site
-
St Albans、澳大利亚、3021
- Research Site
-
Westmead、澳大利亚、2145
- Research Site
-
-
-
-
-
Lima、秘鲁、Lima 32
- Research Site
-
Lima、秘鲁、15038
- Research Site
-
Lima、秘鲁、Lima 34
- Research Site
-
-
-
-
California
-
San Diego、California、美国、92123
- Research Site
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- Research Site
-
-
Florida
-
Stuart、Florida、美国、34994
- Research Site
-
-
Illinois
-
Urbana、Illinois、美国、61801
- Research Site
-
-
Indiana
-
New Albany、Indiana、美国、47150
- Research Site
-
-
Kentucky
-
Lexington、Kentucky、美国、40503
- Research Site
-
Louisville、Kentucky、美国、40241
- Research Site
-
-
Maryland
-
Annapolis、Maryland、美国、21401
- Research Site
-
Baltimore、Maryland、美国、21201
- Research Site
-
Baltimore、Maryland、美国、21229
- Research Site
-
Bethesda、Maryland、美国、20817
- Research Site
-
-
Michigan
-
Grand Rapids、Michigan、美国、49503
- Research Site
-
-
Minnesota
-
Duluth、Minnesota、美国、55805
- Research Site
-
-
Montana
-
Billings、Montana、美国、59101
- Research Site
-
-
New Jersey
-
Ridgewood、New Jersey、美国、07450
- Research Site
-
-
New York
-
Ithaca、New York、美国、14850
- Research Site
-
-
North Carolina
-
Greensboro、North Carolina、美国、27403
- Research Site
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- Research Site
-
Cleveland、Ohio、美国、44124
- Research Site
-
Maumee、Ohio、美国、43537
- Research Site
-
-
Oregon
-
Portland、Oregon、美国、97239
- Research Site
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- Research Site
-
York、Pennsylvania、美国、17403
- Research Site
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57105
- Research Site
-
-
Texas
-
Houston、Texas、美国、77030
- Research Site
-
-
Virginia
-
Charlottesville、Virginia、美国、22908
- Research Site
-
Fairfax、Virginia、美国、22031
- Research Site
-
Fredericksburg、Virginia、美国、22408
- Research Site
-
Richmond、Virginia、美国、23235
- Research Site
-
-
Washington
-
Richland、Washington、美国、99352
- Research Site
-
Spokane、Washington、美国、99204
- Research Site
-
Tacoma、Washington、美国、98405
- Research Site
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- Research Site
-
-
-
-
-
Belfast、英国、BT9 7AB
- Research Site
-
Bristol、英国、BS2 8ED
- Research Site
-
Dundee、英国、DD1 9SY
- Research Site
-
Edinburgh、英国、EH4 2XR
- Research Site
-
London、英国、W6 8RF
- Research Site
-
London、英国、NW1 2PG
- Research Site
-
Middlesbrough、英国、TS4 3BW
- Research Site
-
Poole、英国、BH15 2JB
- Research Site
-
Torquay、英国、TQ2 7AA
- Research Site
-
Truro、英国、TR1 3LJ
- Research Site
-
Wolverhampton、英国、WV10 OQP
- Research Site
-
-
-
-
-
Lisbon、葡萄牙、1998-018
- Research Site
-
Lisbon、葡萄牙、1769-001
- Research Site
-
Lisbon、葡萄牙、1099-023
- Research Site
-
Lisbon、葡萄牙、1400-038
- Research Site
-
Loures、葡萄牙、2674-514
- Research Site
-
Porto、葡萄牙、4200-319
- Research Site
-
-
-
-
-
Barcelona、西班牙、8035
- Research Site
-
Barcelona、西班牙、8003
- Research Site
-
Granada、西班牙、18016
- Research Site
-
Madrid、西班牙、28034
- Research Site
-
Madrid、西班牙、28040
- Research Site
-
Santiago de Compostela、西班牙、15706
- Research Site
-
Valencia、西班牙、46010
- Research Site
-
-
-
-
-
Haiphong、越南、180000
- Research Site
-
Hanoi、越南、100000
- Research Site
-
Ho Chi Minh City、越南、700000
- Research Site
-
-
-
-
-
Changwon-si、韩国、51353
- Research Site
-
Cheongju-si、韩国、28644
- Research Site
-
Seongnam-si、韩国、13620
- Research Site
-
Seoul、韩国、03080
- Research Site
-
Seoul、韩国、03722
- Research Site
-
Seoul、韩国、05505
- Research Site
-
Suwon、韩国、16499
- Research Site
-
Suwon、韩国、16247
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
INCLUSION CRITERIA:
- Participant must be ≥ 18 years at the time of screening.
- Histologically- or cytologically-documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease
- Provision of a tumour tissue sample obtained prior to CRT
- Documented tumour PD-L1 status by central lab
- Documented EGFR and ALK wild-type status (local or central).
- Patients must not have progressed following definitive, platinum based, concurrent chemoradiotherapy
- Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy
- Participants must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D-conforming technique.
- WHO performance status of 0 or 1 at randomization
- Adequate organ and marrow function
EXCLUSION CRITERIA:
- History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥5 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected non-melanoma skin cancer and curatively treated in situ disease, or adequately treated carcinoma in situ or Ta tumours without evidence of disease.
- Mixed small cell and non-small cell lung cancer histology.
- Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC.
- Participants with locally advanced (Stage III) unresectable NSCLC who have progressed during platinum-based cCRT.
- Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy (excluding alopecia).
- Participants with ≥grade 2 pneumonitis from prior chemoradiation therapy.
- History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis - regardless of time of onset prior to randomisation. Evidence of active non-CRT induced pneumonitis (≥ Grade 2), active pneumonia, active ILD, active or recently treated pleural effusion, or current pulmonary fibrosis - diagnosed in the past 6 months prior to randomization.
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm A: Durvalumab and Oleclumab
Durvalumab on Day 1 of each 28-day cycle + Oleclumab on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months |
Durvalumab IV (intravenous infusion) Oleclumab IV (intravenous infusion) |
|
实验性的:Arm B: Durvalumab and Monalizumab
Durvalumab + Monalizumab on Day 1 of each 28-day cycle for up to 12 months. Placebo infusion will be administered on Day 15 of cycles 1 and 2 only |
Durvalumab IV (intravenous infusion) Monalizumab IV (intravenous infusion) Placebo IV (intravenous infusion) |
|
有源比较器:Arm C: Durvalumab and Placebo
Durvalumab on Day 1 of each 28-day cycle + Placebo on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months |
Durvalumab IV (intravenous infusion) Placebo IV (intravenous infusion) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression Free Surival (PFS)
大体时间:Up to 5 years after first patient randomized.
|
Progression Free Survival (PFS) as assessed by BICR, per RECIST 1.1. |
Up to 5 years after first patient randomized.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间:Up to 9 years after first patient randomized
|
Overall survival (OS) |
Up to 9 years after first patient randomized
|
|
Objective response rate (ORR)
大体时间:Up to 5 years after first patient randomized
|
Objective response rate (ORR) per RECIST 1.1 as assessed by BICR |
Up to 5 years after first patient randomized
|
|
Overall survival (OS) at 24 months
大体时间:Up to 9 years after first patient randomized
|
Overall survival (OS) at 24 months |
Up to 9 years after first patient randomized
|
|
Duration of response (DoR)
大体时间:Up to 5 years after first patient randomized
|
Duration of response (DoR) per RECIST 1.1 as assessed by BICR |
Up to 5 years after first patient randomized
|
|
Progression free survival (PFS) at 6, 12, 18, and 24 months
大体时间:From date of randomization until 24 months
|
Progression free survival (PFS) at 6, 12, 18, and 24 months respectively, per RECIST 1.1 as assessed by BICR |
From date of randomization until 24 months
|
|
Time from randomization to second progression (PFS2)
大体时间:Up to 5 years after first patient randomized
|
Time from randomization to second progression (PFS2) |
Up to 5 years after first patient randomized
|
|
Time from randomization to first date of distant metastasis or death (TTDM)
大体时间:Up to 5 years after first patient randomized
|
Time from randomization to first date of distant metastasis or death (TTDM) |
Up to 5 years after first patient randomized
|
|
Time from randomization to start date of first subsequent therapy (TFST)
大体时间:Up to 9 years after first patient randomized
|
Time from randomization to start date of first subsequent therapy (TFST) |
Up to 9 years after first patient randomized
|
|
Progression free survival (PFS) as assessed by Investigator
大体时间:Up to 5 years after first patient randomized
|
Progression free survival (PFS) as assessed by Investigator |
Up to 5 years after first patient randomized
|
|
IHC analysis of PD-L1 TC expression
大体时间:Up to 5 years after first patient randomized
|
IHC analysis of PD-L1 TC expression relative to efficacy outcomes |
Up to 5 years after first patient randomized
|
|
Concentration of Durvalumab
大体时间:From date of randomization until 3 months after date of last IP dose
|
To assess the Pharmacokinetics of Durvalumab when in combination with Monalizumab or Oleclumab - serum peak and trough concentrations |
From date of randomization until 3 months after date of last IP dose
|
|
Anti-drug antibodies (ADAs)
大体时间:From date of randomization until 3 months after date of last IP dose
|
The immunogenicity of durvalumab, oleclumab, and monalizumab as assessed by presence of anti-drug antibodies (ADAs) |
From date of randomization until 3 months after date of last IP dose
|
|
Time to deterioration in pulmonary symptoms (TTFCD)
大体时间:Up to 5 years after last patient randomized
|
Time to deterioration in pulmonary symptoms (TTFCD) |
Up to 5 years after last patient randomized
|
|
Concentration of Oleclumab
大体时间:From date of randomization until 3 months after last dose of IP
|
To assess the Pharmacokinetics of Oleclumab when in combination with Durvulumab - serum peak and trough concentrations |
From date of randomization until 3 months after last dose of IP
|
|
Concentration of Monalizumab
大体时间:From date of randomization until 3 months after last dose of IP
|
To assess the Pharmacokinetics of Monalizumab when in combination with Durvalumab - serum peak and trough concentrations |
From date of randomization until 3 months after last dose of IP
|
合作者和调查者
赞助
调查人员
- 首席研究员:Fabrice Barlesi, MD、Gustave Roussy, Cancer Campus, Grand Paris
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- D9078C00001
- 2021-004346-37 (EudraCT编号)
- 2023-503999-24-00 (注册表标识符:Clinical Trial Information System (CTIS))
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD 共享时间框架
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共享访问标准
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.